PATIENT OR CAREGIVER
Home  |  Privacy Policy  |  Terms and Conditions  |  Contact Medical Information  |  Site Map

Hemodynamic Data in Idiopathic or Heritable Pulmonary Arterial Hypertension (IPAH/HPAH)

Significant Improvement in Hemodynamics1

In 2 prospective, open-label, randomized trials of 8 and 12 weeks' duration, there was significant improvement in hemodynamics for patients who received chronic continuous infusions of epoprostenol plus conventional therapy compared to patients who received conventional therapy alone. Except for 2 patients with NYHA Functional Class II, all patients were Functional Class III or IV. Conventional therapy could include anticoagulants, oral vasodilators, supplemental oxygen, digoxin, and/or diuretics.

* At 8 weeks: epoprostenol n=10, conventional therapy n=11 (n is the number of patients with hemodynamic data). At 12 weeks: epoprostenol n=38, conventional therapy n=30 (n is the number of patients with hemodynamic data).

Denotes statistically significant difference between epoprostenol and conventional therapy groups.

CI: cardiac index; mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; mSAP: mean systemic arterial pressure; SV: stroke volume; TPR: total pulmonary resistance.